Abstract
Lung carcinoids are neuroendocrine tumors representing 1 to 2% of lung cancers. This study outlines the case of a patient with a metastatic lung atypical carcinoid who presented with a pleural effusion and progression of liver metastases after developing resistance to conventional treatments. Personalized functional profiling (PFP), i.e. drug screening, was performed in ex-vivo spheroids obtained from the patient’s liver metastasis to identify potential therapeutic options. The drug screening results revealed cediranib, an antiangiogenic drug, as a hit drug for this patient, from a library of 66 Food and Drug Administration (FDA)-approved and investigational drugs. Based on the PFP results and the reported evidence of clinical efficacy of bevacizumab and capecitabine combination in gastro-intestinal neuroendocrine tumors, this combination was given to the patient. Four months later, the pleural effusion and pleura carcinosis regressed and the liver metastasis did not progress. The patient experienced 2 years of a stable disease under the PFP-guided personalized treatment.
Original language | English |
---|---|
Pages (from-to) | 96-102 |
Number of pages | 7 |
Journal | Cancer Biology and Therapy |
Volume | 23 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2022 |
Keywords
- antiangiogenic therapy
- drug screening
- lung carcinoid
- neuroendocrine tumors
- Personalized functional profiling
- personalized medicine
- pharmacotyping
- precision medicine
- spheroids